Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >ICAM-2/CD102 Protein, Mouse, Recombinant (hFc)
ICAM-2/CD102 Protein, Mouse, Recombinant (hFc)
  • ICAM-2/CD102 Protein, Mouse, Recombinant (hFc)

ICAM-2/CD102 Protein, Mouse, Recombinant (hFc) NEW

Price $700
Package 100μg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-18

Product Details

Product Name: ICAM-2/CD102 Protein, Mouse, Recombinant (hFc) Supply Ability: 10g
Release date: 2024/11/18

Product Introduction

Bioactivity

NameICAM-2/CD102 Protein, Mouse, Recombinant (hFc)
DescriptionICAM-2/CD102 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 50 kDa and the accession number is P35330.
StorageShipping with blue ice.
KeywordsCD-102 | CD 102

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

Recommended supplier

Product name Price   Suppliers Update time
$450.00/100μg
VIP5Y
TargetMol Chemicals Inc.
2024-10-23
$7240.00/1mg
VIP1Y
TargetMol Chemicals Inc.
2024-10-23
$0.00/25Kg
VIP2Y
shandong perfect biotechnology co.ltd
2024-01-10
  • Since: 2011-01-07
  • Address: 36 Washington Street, Wellesley Hills
INQUIRY